Janus Henderson Group
CTNM

Janus Henderson Group’s Contineum Therapeutics CTNM Stock Holding History

Janus Henderson Group’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35.6M Buy
2,734,836
+285,857
+12% +$3.83M 0.02% 472
2025
Q4 		$27.9M Buy
+2,448,979
New +$27.9M 0.01% 529
2025
Q2 		– Sell
-42,499
Closed -$300K – 2514
2025
Q1 		$300K Sell
42,499
-25,821
-38% -$235K ﹤0.01% 2204
2024
Q4 		$1M Buy
+68,320
New +$1.08M ﹤0.01% 1685

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group's CTNM Position: Q1 2026 in Review

Janus Henderson Group increased its Contineum Therapeutics (CTNM) stake by 12% in Q1 2026, buying an estimated $3.83M and bringing the position to 2,734,836 shares worth $35.6M. The position accounts for 0.02% of the portfolio, ranked #472.

Janus Henderson Group first reported a position in CTNM in Q4 2024 and has held it in 4 quarters since. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

  • Janus Henderson Group held 2,734,836 shares of Contineum Therapeutics worth $35.6M as of Q1 2026.
  • Janus Henderson Group bought 285,857 Contineum Therapeutics shares in Q1 2026, an estimated $3.83M.
  • Contineum Therapeutics made up 0.02% of Janus Henderson Group's portfolio in Q1 2026, its #472 holding.
  • Janus Henderson Group first reported a position in Contineum Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • 90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.